SMD and NMD are competitive pathways that contribute to myogenesis: effects on PAX3 and myogenin mRNAs

  1. Chenguang Gong,
  2. Yoon Ki Kim1,
  3. Collynn F. Woeller,
  4. Yalan Tang and
  5. Lynne E. Maquat2
  1. Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA

    Abstract

    UPF1 functions in both Staufen 1 (STAU1)-mediated mRNA decay (SMD) and nonsense-mediated mRNA decay (NMD), which we show here are competitive pathways. STAU1- and UPF2-binding sites within UPF1 overlap so that STAU1 and UPF2 binding to UPF1 appear to be mutually exclusive. Furthermore, down-regulating the cellular abundance of STAU1, which inhibits SMD, increases the efficiency of NMD, whereas down-regulating the cellular abundance of UPF2, which inhibits NMD, increases the efficiency of SMD. Competition under physiological conditions is exemplified during the differentiation of C2C12 myoblasts to myotubes: The efficiency of SMD increases and the efficiency of NMD decreases, consistent with our finding that more STAU1 but less UPF2 bind UPF1 in myotubes compared with myoblasts. Moreover, an increase in the cellular level of UPF3X during myogenesis results in an increase in the efficiency of an alternative NMD pathway that, unlike classical NMD, is largely insensitive to UPF2 down-regulation. We discuss the remarkable balance between SMD and the two types of NMD in view of data indicating that PAX3 mRNA is an SMD target whose decay promotes myogenesis whereas myogenin mRNA is a classical NMD target encoding a protein required for myogenesis.

    Keywords:

    Keywords

    Footnotes

    • Present address: School of Life Sciences and Biotechnology, Korea University, Anam-Dong, Seongbuk-Gu, Seoul 136-701, Republic of Korea.

    • Corresponding author.

      E-MAIL lynne_maquat{at}urmc.rochester.edu; FAX (585) 271-2683.

    • Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.1717309.

    • Supplemental material is available at http://www.genesdev.org.

      • Received July 17, 2008.
      • Accepted November 7, 2008.
    | Table of Contents

    Life Science Alliance